奥希替尼治疗晚期非小细胞肺癌的临床疗效观察

李晓燕

[ 河南省肿瘤医院 ( 郑州大学附属肿瘤医院 )，河南  郑州  450003]

【摘  要】目的：探讨奥希替尼治疗晚期非小细胞肺癌（NSCLC）的临床治疗疗效。方法：选取本院收治的 NSCLC 患者 74 例，按照患 者治疗方式分组，各为 37 例。其中观察组以奥希替尼治疗，对照组常规化疗治疗。比较两组治疗疗效、血清肿瘤标志物指标变 化、生活质量 KPS 评分。结果： 观察组总有效率为 83.78%（31/37），对照组总有效率为 59.46%（22/37），观察组高于对照组 （P ＜ 0.05）。治疗前两组患者血清肿瘤标志物指标对比差异不显著（P ＞ 0.05）；治疗后观察组血清糖链抗原 125（CA125）、癌 胚抗原（CEA）低于对照组（P ＜ 0.05）。治疗前两组 KPS 评分对比差异不显著（P ＞ 0.05）；治疗后观察组 KPS 评分高于对照组 （P ＜ 0.05）。结论：在治疗 NSCLC 中以奥希替尼治疗，可获得理想的治疗效果，能显著降低血清肿瘤因子水平，使患者生活质量 水平得到一定改善。

【关键词】奥希替尼；恶性肿瘤；肺癌；非小细胞癌；治疗疗效

Clinical Efficacy Observation of Osimertinib in the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Li Xiaoyan

[Henan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzhou University), Zhengzhou, Henan 450003, China]

Abstract: Objective: To explore the clinical therapeutic efficacy of osimertinib in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: A total of 74 NSCLC patients admitted to our hospital were selected and divided into two groups according to their treatment methods, with 37 cases in each group. The observation group was treated with osimertinib, while the control group received conventional chemotherapy. The therapeutic efficacy, changes in serum tumor marker levels, and the quality of life as measured by the Karnofsky Performance Status (KPS) score were compared between the two groups. Results: The overall response rate in the observation group was 83.78% (31/37), which was higher than that in the control group, 59.46% (22/37) (P<0.05). There was no significant difference in serum tumor marker levels between the two groups before treatment (P>0.05); after treatment, the levels of serum carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA) in the observation group were lower than those in the control group (P<0.05). There was no significant difference in KPS scores between the two groups before treatment (P>0.05); after treatment, the KPS scores in the observation group were higher than those in the control group (P<0.05). Conclusion: Osimertinib treatment in NSCLC can achieve satisfactory therapeutic outcomes, significantly reduce the levels of serum tumor factors, and improve the quality of life for patients to a certain extent.

Keywords: Osimertinib; Malignant Tumors; Lung Cancer; Non-Small Cell Carcinoma; Therapeutic Efficacy